Innate Pharma S.A. (IDDA.F) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. IDDA.F files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.72% | 30.00% | Pass |
| Interest-bearing investments | 17.51% | 30.00% | Pass |
| Non-permissible income | 47.29% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.60% | 33.00% | Fail |
| Interest-bearing investments | 54.70% | 33.00% | Fail |
| Non-liquid assets | 44.67% | at least 20.00% | Pass |
| Non-permissible income | 47.29% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.60% | 33.33% | Fail |
| Cash + interest-bearing securities | 54.70% | 33.33% | Fail |
| Accounts receivable | 55.33% | 33.33% | Fail |
| Non-permissible income | 47.29% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.60% | 33.33% | Fail |
| Cash + interest-bearing securities | 54.70% | 33.33% | Fail |
| Accounts receivable | 55.33% | 50.00% | Fail |
| Non-permissible income | 47.29% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.59% | 33.00% | Pass |
| Cash + interest-bearing securities | 17.32% | 33.00% | Pass |
| Accounts receivable | 0.20% | 33.00% | Pass |
| Non-permissible income | 47.29% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.70% | 33.00% | Pass |
| Cash + interest-bearing securities | 16.00% | 49.00% | Pass |
| Accounts receivable | 0.18% | 49.00% | Pass |
| Non-permissible income | 47.29% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.70% | 33.33% | Pass |
| Cash + interest-bearing securities | 16.00% | 33.33% | Pass |
| Accounts receivable | 16.18% | 49.00% | Pass |
| Non-permissible income | 47.29% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.20 | NEUTRAL |
| Stochastic %K (14) | 2.56 | BUY |
| CCI (20) | -221.59 | BUY |
| Williams %R (14) | -97.44 | BUY |
| MACD (12,26,9) | -0.04 | SELL |
| ROC (10) | -14.45 | SELL |
| Momentum (10) | -0.25 | SELL |
| EMA (10) | 1.64 | SELL |
| SMA (10) | 1.66 | SELL |
| EMA (20) | 1.67 | SELL |
| SMA (20) | 1.72 | SELL |
| EMA (30) | 1.66 | SELL |
| SMA (30) | 1.70 | SELL |
| EMA (50) | 1.62 | SELL |
| SMA (50) | 1.61 | SELL |
| EMA (100) | 1.55 | SELL |
| SMA (100) | 1.49 | SELL |
| EMA (200) | 1.53 | SELL |
| SMA (200) | 1.45 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.